Included in the formulation
АТХ:J.06.B.B Immunoglobulins specific
J.06.B.B.16 Palivizumab
Pharmacodynamics:
The preparation is a humanized monoclonal antibody IgG1K interacting with the epitope A antigen of the fusion protein (protein F) of the respiratory syncytial virus (RSV).
Inhibits and neutralizes the fusion proteins of the respiratory syncytial virus of subtypes A and B.
Pharmacokinetics:After intramuscular administration, once a month, the elimination half-life is 18 days.
Indications:Used in children with a high risk of infection to prevent infection of the respiratory syncytial virus of subtypes A and B.
X.J10-J18.J12 Viral pneumonia, not elsewhere classified
Contraindications:Individual intolerance.
Carefully:Allergic reactions in the anamnesis.
Pregnancy and lactation:Recommendations for FDA - Category C. Contraindicated in pregnancy and lactation.
Dosing and Administration:Children up to 6 months old, born before 35 weeks of pregnancy;
up to 2 years with hemodynamic significant congenital heart defects.
Intramuscularly in the external lateral region of the thigh at 15 mg / kg - 5 injections with an interval of one month during the seasonal rise in morbidity.
The highest daily dose: 15 mg / kg.
The highest single dose: 15 mg / kg.
Side effects:Central and peripheral nervous system: nervousness.
Respiratory system: runny nose, cough, sneezing, rarely - apnea.
The system of hematopoiesis: leukopenia.
Digestive system: vomiting, diarrhea.
Allergic reactions.
Overdose:Cases of overdose are not described.
Treatment is symptomatic.
Interaction:Clinically significant interactions are not described.
Special instructions:The administration of the drug may be complicated by the development of an immediate-type hypersensitivity reaction, so after the injection it is necessary to monitor the patients for 30 minutes in a room equipped with all means for providing anti-shock therapy.